Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03722927 · ClinicalTrials.gov registry record · Phase 4
The Use Of Liposomal Bupivacaine For Pain Control
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03722927: Completed Phase 4 study, sponsored by Wake Forest University Health Sciences.
NCT03722927 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03722927, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how well the local anesthetic, liposomal bupivacaine, controls postoperative pain after mastectomy and breast reconstruction.
Primary Outcome
This will be measured every 12 hours for the first 48 hours postoperatively by the level of breast pain associated with arm movements while eating on a scale of 0-10 with higher scores denoting worse outcomes.
Interventions
- DRUG Bupivacaine
- DRUG Liposomal Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 4 |
What the finished NCT03722927 record still lists
NCT03722927 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT03722927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03722927 about?
NCT03722927 is a clinical study titled "The Use Of Liposomal Bupivacaine For Pain Control". The purpose of this research study is to determine how well the local anesthetic, liposomal bupivacaine, controls postoperative pain after mastectomy and breast reconstruction.
What is the current status of trial NCT03722927?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2018-06-14. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT03722927?
The interventions under investigation include: Bupivacaine (DRUG), Liposomal Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT03722927?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03722927's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI